



University of Pittsburgh

University of Pittsburgh Cancer Institute

Hillman Cancer Center
Research Pavilion
5117 Centre Avenue
Pittsburgh, PA 15213-1863
412-623-7700
Fax: 412-623-3355

December 14th, 2012

Joseph Elliot, Ph.D.
Managing Director
Epitopoietic Research Corporation (ERC)
1055 E Colorado Blvd., Suite 500
Pasadena, CA 91106 USA

Dear Joe:

Further to our various emails and conversations over the past few weeks, I want to thank you for sharing with me Dr. Daniela Bota's latest clinical results from the GBM patient she has been treating with ERC1671 for the past nine months. The results are truly amazing.

As I have mentioned before, we here at the Brain Tumor Program at the University of Pittsburgh Cancer Institute are very interested in working with ERC on the on both ERC1671 and the GBM6 vaccine in high grade gliomas and low grade gliomas. We would be interested in participating in any planned multi-center clinical trials or in exploring the initiation of a clinical study here in Pittsburgh.

I look forward in discussing further ways in which we can collaborate with you to accelerate the development of your exciting immunotherapies for brain cancer.

Yours truly,

A handwritten signature in black ink, appearing to read "H. Okada".

Hideho Okada, MD, Ph.D.
Professor of Neurological Surgery,
Surgery and Immunology Clinical and Translational Science Institute
University of Pittsburgh School of Medicine
Co-Leader,
Brain Tumor Program University of Pittsburgh Cancer Institute